Le Lézard
Classified in: Health, Science and technology

Radiance Biopharma to Present at LSX World Congress 2024


Presentation on Monday, April 29th at 11:15 AM (London Time)

BOSTON MA / ACCESSWIRE / April 26, 2024 / Radiance Biopharma ("Radiance" or the "Company"), a biopharmaceutical company specializing in the development of novel Antibody Drug Conjugates (ADCs) and Bispecific ADCs (BsADCs) treatments for cancers, today announced that Robert Brooks, JD, Chief Executive Officer of Radiance will present at the LSX World Congress 2024 on Monday, April 29, 2024 at 11:15AM (GMT+1) in London, England.

In addition to the presentation, Mr. Brooks will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, visit https://informaconnect.com/lsx-world-congress/ A replay of the presentation will be made available on the Company's website, www.Radiancebiopharma.com, following the conclusion of the conference.

About LSX World Congress 2024

The 10th LSX World Congress is the leading partnering, strategy and investment event in Europe, with qualified 1:1 partnering at its core. The event brings together the CEOs and senior decision makers from the world's most innovative biopharma, medtech and healthtech companies with investors, senior BD&L teams, R&D leaders and industry KOLs. Together, they share best practice, forge partnerships and investments - all geared at putting capital and ideas to work to help create the world's future medicines and improve patient outcomes.

About Radiance Biopharma, Inc.

Radiance Biopharma Inc. is a biotechnology company focused on the discovery, development and commercialization of Antibody Drug Conjugates and next generation Bispecfic Antibody Drug Conjugates. Radiance's lead asset RB-201 is a 'First in Class' anti-HER2/TROP2 Bispecfic Antibody Drug Conjugate, that has demonstrated significant efficacy in animal studies in various solid tumors. Radiance is planning to conduct a Phase 1 Clinical Trial in early 2025.

For more information, please visit www.Radiancebiopharma.com.

Investor Relations Contact
Radiance Biopharma
[email protected]
Tel: (617) 621-7143

SOURCE: Radiance Biopharma



View the original press release on accesswire.com


These press releases may also interest you

at 07:50
American Express Global Business Travel Reports Strong Q1 2024 Financial Results and Reiterates 2024 Outlook
American Express Global Business Travel, which is operated by Global Business Travel Group, Inc. ("Amex GBT" or the "Company"), a leading B2B software and services company for travel and expense, today announced financial results for the first...

at 07:50
FIS Hosts 2024 Investor Day: Outlines Strategy and Provides Medium-Term Outlook
FIS® , a global leader in financial technology, will host its Investor Day today at 8:30 a.m. Eastern Time. Stephanie Ferris, CEO and President, James Kehoe, CFO, and other members of the executive team will discuss the company's plans to deliver...

at 07:45
Agenus Reports First Quarter 2024 Results
Agenus Inc. ("Agenus") , a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the first quarter 2024. In a concurrent press release accompanying Agenus' earnings announcement, a $100M...

at 07:42
Jumptuit Granted New Artificial Intelligence (AI) and Blockchain Technology Patent by the U.S. Patent and Trademark Office (USPTO)
We are pleased to announce that the U.S. Patent and Trademark Office (USPTO) has awarded Inventor Donald Leka, Founder and CEO of Jumptuit, a new AI and Blockchain technology patent, "SYSTEM AND METHOD OF CORRELATING MULTIPLE DATA POINTS TO CREATE A...

at 07:40
Lokavant Expands Team to Drive Strategic Direction of AI-Based Clinical Trial Feasibility Solution
One year since forming its Advisory Board, Lokavant, the clinical trial intelligence platform company, announces three new members, including Pfizer's Head of Predictive Analytics Jonathan Crowther. The Lokavant Advisory Board brings together...

at 07:36
Teleste and Swarco enhance passenger information across the Västernorrland bus network in Sweden
Teleste and Swarco have entered into a six-year frame agreement on the deliveries of Teleste information displays to Din Tur, the Västernorrland County public transport authority in Sweden. Under this agreement, Teleste will support Swarco in...

More news about Science and technology...


News published on and distributed by: